Clinical trials
Multiple Sclerosis Relapse clinical trials
Below are recruiting multiple sclerosis relapse clinical trials, each written for real people, not researchers. We’re tracking 223 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06261528Enrolling by invitationPhase 1
Light therapy for sleepiness in progressive MS
This trial tests whether a special light therapy can help people with progressive multiple sclerosis who feel sleepy during the day. It aims to improve energy, mood, and sleep patterns.
Dallas, TexasAges 18 years+ - NCT07299019RecruitingPhase 3
Study of orelabrutinib for secondary progressive MS
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Phoenix, ArizonaAges 18–60 - NCT05258396Recruiting
Remyelination study for teens with multiple sclerosis
This study tests whether the brain may “repair” itself (re-myelinate) in children and teens with multiple sclerosis. It uses brain MRI to look for changes and may help clinicians better understand how to treat MS in younger people.
Le Kremlin-BicêtreAges 12–18 - NCT07738120Recruiting
Virtual reality and exercise for multiple sclerosis
This study tests whether using virtual reality along with exercise can help people with multiple sclerosis. It aims to improve physical function and well-being.
PontevedraAges 18 years+ - NCT07225504RecruitingPhase 3
Study of remibrutinib for secondary progressive multiple sclerosis
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Birmingham, AlabamaAges 18–65 - NCT07282574RecruitingPhase 2
Testing a new study drug for progressive MS
This trial tests a new study drug added to your current MS treatment (ocrelizumab) for people with progressive MS. It aims to see if the combination works better than ocrelizumab alone.
Kogarah, New South WalesAges 18–60 - NCT05357781Recruiting
Test immunoglobulin treatment for fatigue in multiple sclerosis
This trial studies whether giving immunoglobulins (antibody medicines) can improve fatigue in people with multiple sclerosis (MS). It will enroll only people whose MS and fatigue are stable and meet specific blood/health criteria.
Bern, Canton of BernAges 18–65 - NCT06554340Recruiting
Exercise study for multiple sclerosis with high blood pressure
This study tests if exercise can improve blood vessel health and daily function in people with multiple sclerosis (MS) who also have high blood pressure. It may help you move better and feel better.
Boston, MassachusettsAges 18 years+ - NCT06599307RecruitingPhase 2
Rituximab for thinking and hand function in advanced MS
This trial tests whether the drug rituximab can help people with secondary progressive MS keep their thinking and hand abilities from getting worse. It is for people with more advanced disability.
Giza, Giza GovernorateAges 18 years+ - NCT07114809Recruiting
Can brain stimulation and virtual reality boost thinking in MS?
This study tests whether a combination of gentle brain stimulation (tDCS) and virtual reality exercises can improve memory and thinking problems in people with multiple sclerosis. If you have mild to moderate disability and no major health issues, you may be able to join.
Genova, ItalyAges 18–65 - NCT06675864RecruitingPhase 1/Phase 2
YTB323 for non-active progressive MS
This trial tests a new treatment called YTB323, which is a type of personalized cell therapy (CAR-T) designed to target your immune system and slow down MS progression. It is for people with non-active progressive MS who have seen their disability worsen recently.
Darlinghurst, New South WalesAges 18–60 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07571304Recruiting
Dual-Task Training for Teens with Multiple Sclerosis
This study tests whether doing two things at once while exercising (like walking while counting) helps teenagers with multiple sclerosis improve balance, coordination, and daily functioning. The goal is to see if this type of training is better than standard exercise for managing MS symptoms.
IstanbulAges 12–18 - NCT02433028Recruiting
Long-term study for MS and related nervous system conditions
This is a long-term hospital study that follows people diagnosed with MS (and a few related conditions) to understand how disease changes over time. You may be asked to have regular check-ups, brain scans, and provide blood samples so researchers can track disease and treatment effects.
Aarau, Canton of AargauAges Any age - NCT07564921Enrolling by invitation
Nutrition and Muscle Strength in Multiple Sclerosis With Swallowing Difficulty
This study looks at how nutritional status and muscle function relate to each other in people with multiple sclerosis who have difficulty swallowing. Understanding this connection may help doctors better support patients with MS who struggle with eating and drinking.
Gaziantep, şehitkamilAges 18–65 - NCT06529406RecruitingPhase 4
Switching from B-cell therapy to ozanimod in MS
This study tests whether people with stable MS who have been on a B-cell depleting therapy for at least 2 years can safely switch to a daily pill called ozanimod. It aims to see if this switch keeps MS under control and may be more convenient.
Aurora, ColoradoAges 18 years+ - NCT05877963RecruitingPhase 3
Ublituximab treatment plan for relapsing multiple sclerosis
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Birmingham, AlabamaAges 18–65 - NCT06143514Recruiting
Study of BRIUMVI in breast milk
This study looks at how much BRIUMVI (ublituximab) gets into breast milk. It helps understand if the drug is safe for breastfed babies whose mothers are already taking it for relapsing multiple sclerosis.
San Francisco, CaliforniaAges 18 years+ - NCT05500963Recruiting
TENS to reduce fatigue in relapsing-remitting multiple sclerosis
This study tests whether TENS, a non-drug device that delivers mild electrical signals through the skin, can reduce fatigue in people with relapsing-remitting multiple sclerosis (MS). It also includes an exercise-training portion and checks safety and comfort during the program.
Boulder, ColoradoAges 18–65 - NCT06501950Recruiting
Measuring silent MS progression with advanced tests
This study is looking for people with MS who are already on a monoclonal antibody therapy. It aims to measure subtle signs of disease progression using advanced tests, even if you feel stable.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT06873464Enrolling by invitation
Brain stimulation to reduce fatigue in multiple sclerosis
This trial tests if a gentle brain stimulation technique (tDCS) can help reduce fatigue and improve quality of life for people with multiple sclerosis. You would receive either real or placebo stimulation over several sessions to see if it helps you feel less tired.
MadridAges 18–75 - NCT07753928Enrolling by invitation
MRI study of brain changes in multiple sclerosis
This study uses MRI scans to measure how the brain changes over time in people with multiple sclerosis (MS). It may help researchers understand why some people with MS experience more disability, which could lead to better treatments.
DresdenAges 18–55 - NCT06195800Recruiting
Biomarkers after stem cell transplant for neurological diseases
This trial looks at biomarkers (biological signs in your blood) in people with immune-mediated neurological diseases. It compares those getting a stem cell transplant to those on high-efficacy MS treatments to understand how these therapies work.
Sheffield, EnglandAges 16 years+ - NCT06586177Recruiting
Study on Long-Term Effects of B Cell Therapies for MS
This study looks at how B cell therapies (a type of medicine for MS) create a long-lasting effect in people with relapsing-remitting multiple sclerosis. It aims to understand how these treatments work over time so doctors can better predict benefits and risks.
DüsseldorfAges 18–60
Hear when a new Multiple Sclerosis Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple sclerosis relapse?
- Yes. Clin2 currently lists 223 recruiting multiple sclerosis relapse studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis relapse trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis relapse trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.